pharma · Chronic obstructive pulmonary disease (COPD) · Partial Epilepsy in Children and Adolescents
Bial Portela &
Bial Portela & Companhia S.A.
Bial Portela & trial registry — 7 ClinicalTrials.gov studies with program phase, status, and indication context.
EU HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Programs
- 7
- Drugs
- 7
- Patents
- 3
Bial Portela & clinical trials
Registry index of 7 ClinicalTrials.gov studies linked to Bial Portela & programs — each row shows trial ID, program name, phase, status, and indication.
Bial Portela & trial registry — 7 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Bial Portela &.
-
BIA-28-6156-111 — Phase 1
Clinical update -
2021/ABM/01/00010 — Phase 3
Clinical update -
2019/ABM/01/00074 — Phase 3
Clinical update -
Placebo, GLUCOPHAGE 500 mg tabletki powlekane — Phase 2
Clinical update -
GLUCOPHAGE 500 mg tabletki powlekane, Placebo — Phase 3
Clinical update -
Eslicarbazepine acetate (BIA 2-093) — Phase 3
Clinical update -
PSMA-11 kit for Ga-68 labelling — Phase 3
Clinical update